These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma. Liu YH; Hu CM; Hsu YS; Lee WH Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074 [TBL] [Abstract][Full Text] [Related]
3. Zhang Z; Zhang H; Liao X; Tsai HI Front Cell Dev Biol; 2023; 11():1147676. PubMed ID: 37152291 [TBL] [Abstract][Full Text] [Related]
4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123 [TBL] [Abstract][Full Text] [Related]
5. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Ying H; Kimmelman AC; Lyssiotis CA; Hua S; Chu GC; Fletcher-Sananikone E; Locasale JW; Son J; Zhang H; Coloff JL; Yan H; Wang W; Chen S; Viale A; Zheng H; Paik JH; Lim C; Guimaraes AR; Martin ES; Chang J; Hezel AF; Perry SR; Hu J; Gan B; Xiao Y; Asara JM; Weissleder R; Wang YA; Chin L; Cantley LC; DePinho RA Cell; 2012 Apr; 149(3):656-70. PubMed ID: 22541435 [TBL] [Abstract][Full Text] [Related]
6. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis. Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282 [TBL] [Abstract][Full Text] [Related]
7. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536 [TBL] [Abstract][Full Text] [Related]
8. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Suzuki T; Kishikawa T; Sato T; Takeda N; Sugiura Y; Seimiya T; Sekiba K; Ohno M; Iwata T; Ishibashi R; Otsuka M; Koike K Cancer Gene Ther; 2022 May; 29(5):505-518. PubMed ID: 33833413 [TBL] [Abstract][Full Text] [Related]
10. Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity. Luo Y; Li X; Ma J; Abbruzzese JL; Lu W Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33668583 [TBL] [Abstract][Full Text] [Related]
11. The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice. Young CC; Baker RM; Howlett CJ; Hryciw T; Herman JE; Higgs D; Gibbons R; Crawford H; Brown A; Pin CL Cell Mol Gastroenterol Hepatol; 2019; 7(1):93-113. PubMed ID: 30510993 [TBL] [Abstract][Full Text] [Related]
12. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Ramakrishnan G; Parajuli P; Singh P; Friend C; Hurwitz E; Prunier C; Razzaque MS; Xu K; Atfi A Cell Rep; 2022 Nov; 41(6):111623. PubMed ID: 36351408 [TBL] [Abstract][Full Text] [Related]
13. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-Catenin Gao C; Chen G; Zhang DH; Zhang J; Kuan SF; Hu W; Esni F; Gao X; Guan JL; Chu E; Hu J Cell Mol Gastroenterol Hepatol; 2019; 8(4):561-578. PubMed ID: 31330317 [TBL] [Abstract][Full Text] [Related]
14. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264 [TBL] [Abstract][Full Text] [Related]